Lakefront Biotherapeutics Appoints Eric Hedrick, MD, as Chief Medical Officer

On June 8, 2026, Lakefront Biotherapeutics NV (formerly Galapagos) announced the appointment of Eric Hedrick, MD, as Chief Medical Officer. Dr. Hedrick will report to CEO Henry Gosebruch and join the Company’s Management Committee. This appointment follows Lakefront's strategic transformation and its recent acquisition of Ouro Medicines' operational assets, which was announced on June 4, 2026. Dr. Hedrick previously served as Lakefront's clinical evaluation lead since July 2025 and has held high-level medical leadership roles at EQRx, BeiGene, Epizyme, and Pharmacyclics. In his new role, he will be responsible for guiding the development of gamgertamig, which is now considered the cornerstone of Lakefront’s R&D pipeline, as well as overseeing future clinical programs. The company continues to focus on oncology, immunology, and inflammation programs following its rebranding and recent business development activities.